Toyota|$17.53 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$21.48 (¥3,465)-0.14%▼ (in JPY terms)
SoftBank|$35.50 (¥5,727)+5.59%▲ (in JPY terms)
MUFG|$21.94 (¥3,540)+1.93%▲ (in JPY terms)
Keyence|$448.44 (¥72,350)+2.07%▲ (in JPY terms)
Nintendo|$43.28 (¥6,982)-4.28%▼ (in JPY terms)
NTT|$0.94 (¥152)+0.66%▲ (in JPY terms)
Takeda|$34.42 (¥5,554)+1.35%▲ (in JPY terms)
Tokyo Electron|$409.27 (¥66,030)+1.43%▲ (in JPY terms)
Recruit|$79.03 (¥12,750)-0.55%▼ (in JPY terms)
ITOCHU|$12.05 (¥1,945)+2.21%▲ (in JPY terms)
Honda|$9.63 (¥1,553)+1.14%▲ (in JPY terms)
Shin-Etsu|$44.63 (¥7,200)+0.60%▲ (in JPY terms)
Tokio Marine|$48.60 (¥7,841)+4.19%▲ (in JPY terms)
Fast Retailing|$497.22 (¥80,220)+1.75%▲ (in JPY terms)
Toyota|$17.53 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$21.48 (¥3,465)-0.14%▼ (in JPY terms)
SoftBank|$35.50 (¥5,727)+5.59%▲ (in JPY terms)
MUFG|$21.94 (¥3,540)+1.93%▲ (in JPY terms)
Keyence|$448.44 (¥72,350)+2.07%▲ (in JPY terms)
Nintendo|$43.28 (¥6,982)-4.28%▼ (in JPY terms)
NTT|$0.94 (¥152)+0.66%▲ (in JPY terms)
Takeda|$34.42 (¥5,554)+1.35%▲ (in JPY terms)
Tokyo Electron|$409.27 (¥66,030)+1.43%▲ (in JPY terms)
Recruit|$79.03 (¥12,750)-0.55%▼ (in JPY terms)
ITOCHU|$12.05 (¥1,945)+2.21%▲ (in JPY terms)
Honda|$9.63 (¥1,553)+1.14%▲ (in JPY terms)
Shin-Etsu|$44.63 (¥7,200)+0.60%▲ (in JPY terms)
Tokio Marine|$48.60 (¥7,841)+4.19%▲ (in JPY terms)
Fast Retailing|$497.22 (¥80,220)+1.75%▲ (in JPY terms)

admin

2026-07-14 Eisai Co.,Ltd. “New findings on Etalanetug (E2814) will be presented at AAIC 2026 – Etalanetug reduces eMTBR-tau243, a blood biomarker specific to tau aggregates in Alzheimer's disease – Measuring the blood biomarker eMTBR-tau243 may be a practical and minimally invasive method for capturing pathological changes specific to Alzheimer's disease, and is expected to play an important role in the future clinical development of etalanetug.”

by

2026-07-14 Eisai Co.,Ltd. “New findings on Etalanetug (E2814) will be presented at AAIC 2026 – Etalanetu … 続きを読む

2026-07-14 Eisai Co.,Ltd. “LEQEMBI IQLIK®, a subcutaneous injection formulation of the anti-Aβ antibody LEQEMBI®, has received approval from the U.S. FDA as an initial treatment for early-stage Alzheimer's disease. LEQEMBI IQLIK is the world's first and only anti-amyloid therapy that offers the convenience of home administration from initial treatment to maintenance therapy. LEQEMBI IQLIK is scheduled to be launched in the U.S. in late August 2026 as an initial treatment.”

by

2026-07-14 Eisai Co.,Ltd. “LEQEMBI IQLIK®, a subcutaneous injection formulation of the anti-Aβ antibody … 続きを読む

2026-07-14 Oji Holdings Corporation “News release dated July 14, 2026: Management/Finance – Continued selection as a constituent stock of the "FTSE4Good Index Series," "FTSE JPX Blossom Japan Index," and "FTSE JPX Blossom Japan Sector Relative Index."”

by

2026-07-14 Oji Holdings Corporation “News release dated July 14, 2026: Management/Finance – Contin … 続きを読む

Contact